Europe Medical Cannabis Market Introduction and Overview
According to SPER Market Research, the Europe Medical Cannabis Market is estimated to reach USD 58.11 billion by 2033 with a CAGR of 24.3%.
The report includes an in-depth analysis of the Europe Medical Cannabis Market, including market size and trends, product mix, distribution channels, and supplier analysis. The cannabis plant, which belongs to the Cannabaceae family, is the source of the psychoactive substance known as cannabis. It is used medicinally and has been for a while. Treatments for chronic pain, cancer, depression, diabetes, glaucoma, arthritis, migraines, AIDS, and Alzheimer's are just a few of the conditions for which it is used.
- Tilray declared in May 2020 that it had obtained GMP certification in accordance with EU regulations, enabling the establishment to produce medical cannabis extracts on-site and export completed medical cannabis products. This facilitated the company's growth.
- Sanity Group GmbH, a division of Sanity Medical, and Telaleaf, a telemedicine platform, signed a partnership in February 2022 to advance telemedicine in cannabis therapy in Germany.
Market Opportunities and Challenges
Opportunities: One of the primary factors supporting a favorable market outlook is the rising incidence of chronic illnesses like cancer, arthritis, Alzheimer's, and migraines. Moreover, the industry is expanding due to the increased use of medical cannabis for pain relief. To numb pain receptors and give patients immediate comfort, it is typically smoked, inhaled, taken orally, or used topically. Furthermore, the legalization of medicinal marijuana in Europe has improved the products' accessibility through medical facilities and licensed outlets, which has fueled market expansion. It is projected that additional factors will propel the market, such as intensive research and development (R&D) efforts aimed at optimizing the use of cannabinoids and advancements in the healthcare infrastructure.
Challenges: Effects of Cannabis Use and Overuse: Short- and Long-Term Side Effects Following the use of the implants and drugs, orthopedic professionals note certain hazards. Complications from surgery or an implant gone wrong are delivered by the knee replacement surgeries. Among the most serious side effects following knee surgery is a loose implant; discomfort is the most frequent one. Serious falls, instability, and fractures of the bones can result from loosening. Surgery for revision is necessary for almost all major problems. Mechanical concerns, physical pain, and loosening of the knee implant are the risks.
Market Competitive Landscape
The Medical Cannabis market in Europe is moderately consolidated. Some of the market key players are Tilray, Althea Company Pty Ltd (A subsidiary of Althea Group Holdings Limited), PharmaHemp, Aurora Cannabis Inc., CANOPY GROWTH CORPORATION.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Species, By Derivative, By Application, By End Use, By Route of Administration
|
| Regions covered | UK, France, Germany, Italy, Spain, Rest of Europe
|
| Companies Covered | Tilray, Althea Company Pty Ltd (A subsidiary of Althea Group Holdings Limited), Jazz Pharmaceuticals, Inc., EcoGen Biosciences, GRASS & CO., PharmaHemp, Aurora Cannabis Inc., CANOPY GROWTH CORPORATION, CANNARAY, and Sanity Group GmbH among others
|
COVID-19 Impact on Europe Medical Cannabis Market
The COVID-19 epidemic had a major effect on Europe's medical cannabis business, posing both opportunities and obstacles. Lockdowns and other regulations originally caused supply chains to break and made it more difficult for patients to obtain medical cannabis products, but they also led to changes in regulations and a rise in the adoption of telemedicine consultations, which made medical cannabis more widely accessible to those in need. Additionally, some European nations accelerated the legalization or development of medicinal cannabis programs in an effort to profit from the industry's potential economic benefits as governments looked for cash sources to lessen economic downturns.
Key Target Audience:
- Healthcare Professionals
- Patients and Caregivers
- Government Regulators and Policymakers
- Medical Cannabis Producers and Distributors
- Pharmaceutical Companies
- Research Institutions and Academia
Our in-depth analysis of the Europe Medical Cannabis Market includes the following segments:
|
By Species: |
Indica
Sativa
Hybrid
|
|
By Derivative: |
Cannabidiol (CBD)
Tetrahydrocannabinol (THC)
Others
|
|
By Application: |
Cancer
Arthritis
Migraine
Epilepsy
Others
|
|
By End Use: |
Pharmaceutical Industry
Research and Development Centers
Others
|
|
By Route of Administration: |
Oral Solutions and Capsules
Smoking
Vaporizers
Topicals
Others
|
Key Topics Covered in the Report:
- Europe Medical Cannabis Market Size (FY’2024-FY’2033)
- Overview of Europe Medical Cannabis Market
- Segmentation of Europe Medical Cannabis Market By Species (Indica, Sativa, Hybrid)
- Segmentation of Europe Medical Cannabis Market By Derivative (Cannabidiol Tetrahydrocannabinol Others)
- Segmentation of Europe Medical Cannabis Market By Application (Cancer, Arthritis, Migraine, Epilepsy, Others)
- Segmentation of Europe Medical Cannabis Market By End Use (Pharmaceutical Industry, Research and Development Centers, Others)
- Expansion Analysis of Europe Medical Cannabis Market
- Problems and Obstacles in Europe Medical Cannabis Market
- Competitive Landscape in the Europe Medical Cannabis Market
- Impact of COVID-19 and Demonetization on Europe Medical Cannabis Market
- Details on Current Investment in Europe Medical Cannabis Market
- Competitive Analysis of Europe Medical Cannabis Market
- Prominent Players in the Europe Medical Cannabis Market
- SWOT Analysis of Europe Medical Cannabis Market
- Europe Medical Cannabis Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Europe Medical Cannabis Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Europe Medical Cannabis Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Europe Medical Cannabis Market
7. Europe Medical Cannabis Market, By Species (USD Million) 2020-2033
7.1. Europe Medical Cannabis Market Size, Share and Forecast, By Species, 2020-2026
7.2. Europe Medical Cannabis Market Size, Share and Forecast, By Species, 2027-2033
7.3. Indica
7.4. Sativa
7.5. Hybrid
8. Europe Medical Cannabis Market, By Derivative (USD Million) 2020-2033
8.1. Europe Medical Cannabis Market Size, Share and Forecast, By Derivative, 2020-2026
8.2. Europe Medical Cannabis Market Size, Share and Forecast, By Derivative, 2027-2033
8.3. Cannabidiol (CBD)
8.4. Tetrahydrocannabinol (THC)
8.5. Others
9. Europe Medical Cannabis Market, By Application (USD Million) 2020-2033
9.1. Europe Medical Cannabis Market Size, Share and Forecast, By Application, 2020-2026
9.2. Europe Medical Cannabis Market Size, Share and Forecast, By Application, 2027-2033
9.3. Cancer
9.4. Arthritis
9.5. Migraine
9.6. Epilepsy
9.7. Others
10. Europe Medical Cannabis Market, By End Use (USD Million) 2020-2033
10.1. Europe Medical Cannabis Market Size, Share and Forecast, By End Use, 2020-2026
10.2. Europe Medical Cannabis Market Size, Share and Forecast, By End Use, 2027-2033
10.3. Pharmaceutical Industry
10.4. Research and Development Centers
10.5. Others
11. Europe Medical Cannabis Market, By Route of Administration (USD Million) 2020-2033
11.1. Europe Medical Cannabis Market Size, Share and Forecast, By Route of Administration, 2020-2026
11.2. Europe Medical Cannabis Market Size, Share and Forecast, By Route of Administration, 2027-2033
11.3. Oral Solutions and Capsules
11.4. Smoking
11.5. Vaporizers
11.6. Topicals
11.7. Others
12. Europe Medical Cannabis Market Forecast, 2020-2033 (USD Million)
12.1. Europe Medical Cannabis Market Size and Market Share
13. Europe Medical Cannabis Market, By Region, 2020-2033 (USD Million)
13.1. Europe Medical Cannabis Market Size and Market Share By Region (2020-2026)
13.2. Europe Medical Cannabis Market Size and Market Share By Region (2027-2033)
13.3. France
13.4. Germany
13.5. Italy
13.6. United Kingdom
13.7. Rest of Europe
14. Company Profile
14.1. Althea Company Pty Ltd
14.1.1. Company details
14.1.2. Financial outlook
14.1.3. Product summary
14.1.4. Recent developments
14.2. Aurora Cannabis Inc.
14.2.1. Company details
14.2.2. Financial outlook
14.2.3. Product summary
14.2.4. Recent developments
14.3. CANOPY GROWTH CORPORATION
14.3.1. Company details
14.3.2. Financial outlook
14.3.3. Product summary
14.3.4. Recent developments
14.4. CANNARAY
14.4.1. Company details
14.4.2. Financial outlook
14.4.3. Product summary
14.4.4. Recent developments
14.5. EcoGen Biosciences
14.5.1. Company details
14.5.2. Financial outlook
14.5.3. Product summary
14.5.4. Recent developments
14.6. GRASS & CO.
14.6.1. Company details
14.6.2. Financial outlook
14.6.3. Product summary
14.6.4. Recent developments
14.7. Jazz Pharmaceuticals, Inc.
14.7.1. Company details
14.7.2. Financial outlook
14.7.3. Product summary
14.7.4. Recent developments
14.8. PharmaHemp
14.8.1. Company details
14.8.2. Financial outlook
14.8.3. Product summary
14.8.4. Recent developments
14.9. Sanity Group GmbH
14.9.1. Company details
14.9.2. Financial outlook
14.9.3. Product summary
14.9.4. Recent developments
14.10. Tilray
14.10.1. Company details
14.10.2. Financial outlook
14.10.3. Product summary
14.10.4. Recent developments
14.11. Others
17. Conclusion
15. List of Abbreviations
16. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
